drugset
drugset / Trial / NCT00004022

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

NCT00004022 ↗

Phase 2 Completed Barbara Ann Karmanos Cancer Institute National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating patients who have stage III or stage IV melanoma.

Timeline

Start
1997-06
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — Intravenous
Subject autologous tumor cell vaccine Vaccine — —
Subject therapeutic autologous lymphocytes Cell therapy — Intravenous
Background OKT3 Monoclonal antibody — —

Indications

cutaneous melanoma